Member Info for Krone

Hi Fadec - thanks.

The European Patent Office details were updated on 30/10/2020.
https://register.epo.org/ipfwretrieve?apn=US.201716343639.A&lng=en
The document provides a detailed summary of the response to the challenges:
https://register.epo.org/documentView?number=US.201716343639.A&documentId=2-4-US++163436390ZP1+
The document refers to SAR20351 as an immunotherapeutic in the context of the treatment of cancers. The earlier SRI work refers to SAR20351 in the context of the treatment of lupus. https://apps.dtic.mil/sti/pdfs/AD1087498.pdf
Not sure whether SAR20351 has potential in both cancer and lupus?
Assuming the USPO accepts the clarification we appear to be nearing final conclusion of the patent which would be excellent news!!

Hear! Hear!

AndytheMKDon - thank you, that’s what I was driving at. Given the situation there’ll be no delaying the development of what could be a massively important addition to the treatment options available.

In response to a written question regarding the timelines for the development of SDC1801 in Covid, Tim/John state:
"This would follow the normal pattern for any development programme, albeit with the opportunity to compress timeframes depending on levels of funding and support....... "Given the pressing need for new therapies to treat Covid-19, it may be that there will be accelerated paths to approval"
It must be safe to assume that timelines will be compressed as much as clinically appropriate so the question is whether the 6 months grant funding referred to in the RNS is based on a compressed timeline and if not, by how much could the timeline be shortened?

Q18: Can you describe the process of progressing SDC-1801 in COVID trials?

This would follow the normal pattern for any development programme, albeit with the opportunity to compress timeframes depending on levels of funding and support.
The grant funding, if our application is successful, would cover the initial lab and other preclinical studies that aim to demonstrate that our molecules are effective against the overactive immune response seen in Covid-19 (and other viral respiratory infections). If and when that is achieved – and also considering the safety/tox and other data from the formal preclinical studies - we will look to incorporate the successful molecules into the clinical trial programme being run by UKRI as quickly as possible.
Phase 1 clinical studies would be needed to demonstrate safety in healthy volunteers, before moving on to look at efficacy in later stage studies.
Given the pressing need for new therapies to treat Covid-19, it may be that there will be accelerated paths to approval.

BoilB - just tweeted by Hybridan!

More support for @Sareumplc #SAR $SAR.L and the potential for SDC 1801 as a treatment for the symptoms of COVID-19
https://twitter.com/hybridanllp/status/1322098821447516160?s=21

BoilB - nice find!

DBX deposit c £16k - full spec c £200k - I’ve checked!!

More thrust Scottie !

Hi RMM - given the current perilous state of the world it must be reasonable to assume that 1801 for Covid will be fast tracked within the constraints of proper scientific rigour. It is inconceivable that we are not flashing brightly on the radar of many big pharma companies.

Hi RMM - Outstanding post, many thanks.

We have developed intellectual property in several early stage discoveries. Research on these is currently on hold while we invest in our more advanced development programmes.

VEGFR-3 kinase
VEGFR-3 (Vascular Endothelial Growth Factor Receptor 3 Kinase), also known at FLT4, is involved in the generation of new blood and lymph vessels to a tumour. It is often over produced in many different types of cancer including:

lung
gastric
prostate
Lymph vessels are known to be a major route of metastasis. Inhibitors of VEGFR-3 therefore have the potential to reduce, delay or inhibit the spread of cancer throughout the body. We have discovered a series of compounds that demonstrate potent inhibition of lymph cell growth by selectively inhibiting VEGFR-3.

Fatty Acid Synthase - FASN
Cancer cells increase their consumption of sugars, fats and amino acids to satisfy the demands of continuous growth and multiplication. FASN, which controls the production of fatty acids, was first proposed as an anti-cancer target in 1994. FASN has been found to be over-produced in most types of solid tumour and has been linked to poor patient prognosis. Many cancer cell types can be destroyed by blocking FASN activity making it an attractive target for treating many types of cancer.

The exploration into our FASN research programme received £150,000 from the Technology Strategy Board. Programme compounds have demonstrated promising results in models of breast and colon cancer.

ALK Kinase
Anaplastic Lymphoma Kinase (ALK) is over active in Anaplastic Large Cell Lymphoma (ALCL, a type of non-Hodgkins Lymphoma), as well as certain lung cancers and childhood neuroblastomas. Sareum’s compounds, which were discovered from its SKIL platform, are potent against cancer cell types that have overactive ALK function.

FLT3 Kinase
Sareum has used its SKIL platform to develop a novel chemical series that inhibits the activity of FLT3 kinase and is highly selective against a panel of other kinases. These have potential use against certain types of leukaemia as well as autoimmune disorders such as Rheumatoid Arthritis and Multiple Sclerosis.

Microtubule Binding Agents
This programme arose from our SKIL library. Our lead compounds act in a similar way to the billion-dollar selling taxane class of cancer drugs. However, in contrast to taxanes, which are natural product derivatives, our Microtubule Binding Agents are entirely synthetic and can be dosed orally. They show significant potent activity against a range of colon, lung, breast & prostate cancer and leukaemia cell types.

Late trades from yesterday
27-Oct-20 13:53:57 2.298 1,000,000 Buy* 2.05 2.20 22.98k O
27-Oct-20 08:01:57 2.202 1,044,772 Buy* 2.05 2.20 23.01k O
27-Oct-20 08:37:25 2.86 971,693 Buy* 2.05 2.20 27.79k O
27-Oct-20 11:07:32 2.87 848,487 Buy* 2.05 2.20 24.35k O
27-Oct-20 09:37:33 2.85 1,000,000 Buy* 2.05 2.20 28.50k O
27-Oct-20 09:53:01 2.90 5,000,000 Buy* 2.05 2.20 145.00k O
27-Oct-20 08:43:52 2.85 912,300 Buy* 2.05 2.20 26.00k O
27-Oct-20 11:59:12 1.75 1,714,626 Sell* 2.05 2.20 30.01k O
27-Oct-20 13:51:52 2.305 1,000,000 Buy* 2.05 2.20 23.05k O
27-Oct-20 11:59:36 1.75 1,574,237 Sell* 2.05 2.20 27.55k O
27-Oct-20 11:11:44 2.53 1,186,107 Buy* 2.05 2.20 30.01k O
27-Oct-20 12:25:31 1.70 2,000,000 Sell* 2.05 2.20 34.00k O
27-Oct-20 08:51:32 2.86 1,221,071 Buy* 2.05 2.20 34.92k O
27-Oct-20 11:46:43 1.66 2,000,000 Sell* 2.05 2.20 33.20k O
27-Oct-20 11:28:19 2.26 990,000 Buy* 2.05 2.20 22.37k O
27-Oct-20 11:52:42 1.65 2,294,908 Sell* 2.05 2.20 37.87k O
27-Oct-20 11:45:11 1.86 1,500,000 Sell* 2.05 2.20 27.90k O
27-Oct-20 08:55:35 2.9554 1,653,212 Buy* 2.05 2.20 48.86k O
27-Oct-20 09:36:45 2.841 1,181,884 Buy* 2.05 2.20 33.58k O
27-Oct-20 11:11:58 2.50 1,000,000 Buy* 2.05 2.20 25.00k O
27-Oct-20 13:05:25 2.36 2,000,000 Buy* 2.05 2.20 47.20k O
27-Oct-20 08:17:57 2.4206 1,235,594 Buy* 2.05 2.20 29.91k O
27-Oct-20 11:10:14 2.665 1,500,000 Buy* 2.05 2.20 39.98k O
27-Oct-20 08:09:21 2.215 1,000,000 Buy* 2.05 2.20 22.15k O
27-Oct-20 11:54:09 1.80 2,000,000 Sell* 2.05 2.20 36.00k O
27-Oct-20 09:14:01 2.676 1,000,000 Buy* 2.05 2.20 26.76k O
27-Oct-20 08:58:25 2.90 1,000,000 Buy* 2.05 2.20 29.00k O
27-Oct-20 13:45:21 2.31 1,000,000 Buy* 2.05 2.20 23.10k O
27-Oct-20 12:42:34 2.0425 1,328,749 Sell* 2.05 2.20 27.14k O
27-Oct-20 11:08:57 2.80 2,000,000 Buy* 2.05 2.20 56.00k O
27-Oct-20 11:41:22 2.05 1,170,293 Sell* 2.05 2.20 23.99k O
27-Oct-20 10:55:57 2.95 1,016,510 Buy* 2.05 2.20 29.99k O
27-Oct-20 12:50:12 2.031 1,101,653 Sell* 2.05 2.20 22.37k O
27-Oct-20 10:25:48 2.935 851,329 Buy* 2.05 2.20 24.99k O
27-Oct-20 11:45:24 1.866 1,285,798 Sell* 2.05 2.20 23.99k O
27-Oct-20 11:46:15 1.73 1,569,919 Sell* 2.05 2.20 27.16k O
27-Oct-20 11:46:23 1.73 1,997,236 Sell* 2.05 2.20 34.55k O
27-Oct-20 11:14:23 2.625 951,394 Buy* 2.05 2.20 24.97k O
27-Oct-20 13:05:51 2.6275 1,418,003 Buy* 2.05 2.20 37.26k O
27-Oct-20 12:44:24 2.198 3,000,000 Buy* 2.05 2.20 65.94k O
27-Oct-20 11:04:56 3.00 1,500,000 Buy* 2.05 2.20 45.00k O
27-Oct-20 11:35:12 2.10 2,500,000 Sell* 2.05 2.20 52.50k O
27-Oct-20 08:49:46 3.06 700,000 Buy* 2.05 2.20 21.42k O
27-Oct-20 16:07:54 2.19 1,609,589 Buy* 2.05 2.20 35.25k O
27-Oct-20 08:50:27 2.955 1,421,447 Buy* 2.05 2.20 42.00k O
27-Oct-20 11:13:46 2.6025 1,000,000 Buy* 2.05 2.20 26.03k O
27-Oct-20 15:37:38 2.215 1,418,003 Buy* 2.05 2.20 31.41k O
27-Oct-20 14:25:31 2.36 1,000,000 Buy* 2.05 2.20 23.60k

Very interesting!

Hi Working - that’s what I thought. They have allegedly been trying to identify non-dilutive funding since June 2019. The tone has recently changed, according to Tim, in that they are now looking to find in-house. The contract provides for return of the asset if Sierra fail to make all reasonable commercial efforts to progress, or words to that effect. To the layman it appears that they have done sweet sod all despite the various papers authored by ICR De Bono, Kristeleit and Triparna Sen. One hopes that Stephen Parker is very much on the case!

Thoth - that’s September 2020, correct?

Sareum tweet from earlier in the year Re Covid related Sepsis https://twitter.com/sareumplc/status/1252183089067016193?s=21

Basil - It would be hard to draft a more bland and low key tweet. This is either incompetence on the part of the people responsible for Sar's PR or there is a bigger picture. https://twitter.com/Sareumplc/status/1321087847630331906?s=20

We’ll soon be able to make a hostile takeover bid for Sierra, ditch momly and repatriate 737....

Interesting question posed by JMo123 on Stocktwits:
How excited do we get that Sierra is advertising for a new Clinical Trials Manager and one requirement is the person be able to do this?!!
"Review of study protocols to develop specific and measurable Clinical Operational plans including study timelines and budget for milestones and deliverables"

The momentum trials are well underway so could this relate to further SRA737 trials?